Formulated.

Formulated for
cost reform.

Cost of cancer care represents a significant financial burden to patients. Price increases have driven up the cost of oncology supportive care.1

Next

Neulasta® (pegfilgrastim) Historical Prices in the US1

Pegfilgrastim WAC

Consumer Price Index*

Wholesale acquisition cost (WAC) has more than doubled since 2006+132%

+27%

Competition
for a change

Competition for a change

A major contributor to the rising cost of care, biologics account for 40% of prescription drug spending in the United States, which reached a record $425 billion in 2015.2 Biosimilars such as UDENYCA may positively impact patients, providers, and the healthcare system at large.

Benefits of Biosimilars

PROVIDERS2,3

  • Provides a choice that has the potential to lower the financial burden
  • May help increase patient access

PATIENTS2,3

  • Helps decrease overall financial burden
  • Increases access to treatment options

SYSTEM2,3

  • Offsets the burden of increasing healthcare costs in areas such as oncology
  • Potential savings due to more treatment choices and increased competition
  • May free up resources for other important aspects of healthcare

PROVIDERS2,3

  • Provides a choice that has the potential to lower the financial burden
  • May help increase patient access

PATIENTS2,3

  • Helps decrease overall financial burden
  • Increases access to treatment options

SYSTEM2,3

  • Offsets the burden of increasing healthcare costs in areas such as oncology
  • Potential savings due to more treatment choices and increased competition
  • May free up resources for other important aspects of healthcare

UDENYCA offers SIGNIFICANT COST SAVINGS for your patients and practice4

Wholesale Acquisition Cost (WAC)

Neulasta®

~$6200

UDENYCA

$4175

UDENYCA delivers high-quality treatment and the reliable outcomes that you expect with Neulasta®, but with 32% cost savings
for your patients and practice.4,5

UDENYCA delivers high-quality treatment and the reliable outcomes that you expect with Neulasta®, but with 32% cost savings for your patients and practice.4,5

References: 1. United States Bureau of Labor Statistics. SHA National Data, MAT. January 2018. 2. The Biosimilars Council. Biosimilars: a safe & effective option for patients. The Biosimilars Council website. http://biosimilarscouncil.org/wp-content/uploads/2017/11/Biosimilars-Fact-Sheet_Updated-10-9-17-Final.pdf. Accessed July 26, 2018. 3. Biosimilars overview. Biosimilars Forum website. http://www.biosimilarsforum.org/sites/default/files/uploads/image-Resources/biosimilars_overview_02_28_17_v1.pdf. Accessed July 26, 2018. 4. First Databank, Inc. Pricing Compendia. 5. UDENYCA (pegfilgrastim-cbqv) package insert. Redwood City, CA: Coherus BioSciences, Inc.; 2018.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION:

Patients with a history of serious allergic reaction to human granulocyte colony-stimulating factors such as pegfilgrastim or filgrastim products.

    WARNINGS AND PRECAUTIONS:

  • Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture.
  • Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress. Discontinue UDENYCA in patients with ARDS.
  • Serious allergic reactions, including anaphylaxis: Permanently discontinue UDENYCA in patients with serious allergic reactions.
  • Fatal sickle cell crises: Have occurred.
  • Glomerulonephritis: Evaluate and consider dose-reduction or interruption of UDENYCA if causality is likely.

ADVERSE REACTIONS:

Most common adverse reactions (≥ 5% difference in incidence compared to placebo) are bone pain and pain in extremity.

To report SUSPECTED ADVERSE REACTIONS, contact Coherus BioSciences at 1-800-4-UDENYCA (1-800-483-3692) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATION

UDENYCA is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Limitations of Use
UDENYCA is not indicated for the mobilization of peripheral blood progenitor cells or hematopoietic stem cell transplantation.

Please see Full Prescribing Information, Patient Information, and Instructions for Use.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION:

Patients with a history of serious allergic reaction to human granulocyte colony-stimulating factors such as pegfilgrastim or filgrastim products.

    WARNINGS AND PRECAUTIONS:

  • Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture.
  • Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress. Discontinue UDENYCA in patients with ARDS.
  • Serious allergic reactions, including anaphylaxis: Permanently discontinue UDENYCA in patients with serious allergic reactions.
  • Fatal sickle cell crises: Have occurred.
  • Glomerulonephritis: Evaluate and consider dose-reduction or interruption of UDENYC if causality is likely.

ADVERSE REACTIONS:

Most common adverse reactions (≥ 5% difference in incidence compared to placebo) are bone pain and pain in extremity.

To report SUSPECTED ADVERSE REACTIONS, contact Coherus BioSciences at 1-800-4-UDENYCA (1-800-483-3692) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATION

UDENYCA is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Limitations of Use
UDENYCA is not indicated for the mobilization of peripheral blood progenitor cells or hematopoietic stem cell transplantation.

Please see Full Prescribing Information, Patient Information, and Instructions for Use.